Neuralstem’s (NASDAQ: CUR) preclinical data on NSI-189 was recently published in the Journal of Cellular Physiology. The study demonstrated that NSI-189 improved behavioral function recovery and enhanced hippocampal synaptic plasticity in stroke-induced animals during the 12-week treatment period, which was maintained up to 24 weeks post-stroke. The study demonstrated that in neurologic and motor deficit tests, the animals treated with NSI-189 performed significantly better than the placebo animals. Additionally, the animals treated with NSI-189 continued to improve during the second 12-week period even in the absence of drug treatment. Histological assessment of stroke-induced brains from NSI-189-treated subjects suggest that NSI-189 actively stimulated endogenous remodeling of the stroke-induced brain. “These data add to the growing body of evidence demonstrating NSI-189’s ability to promote neurogenic, synaptogenic plasticity in various disease models. Our data also indicate temporary treatment with NSI-189 can lead to long-lasting structural repair and suggest continued durability of functional improvements by NSI-189, even after NSI-189 treatment had ceased,” Neuralstem Chief Scientific Officer Karl Johe, Ph.D. stated in the news release.
To view the full press release, visit: http://nnw.fm/wE11G
About Neuralstem
Neuralstem’s patented technology enables the commercial-scale production of multiple types of central nervous system stem cells, which are being developed as potential therapies for multiple central nervous system diseases and conditions. Neuralstem’s technology enables the discovery of small molecule compounds by systematic screening chemical compounds against its proprietary human hippocampal stem cell line. The screening process has led to the discovery and patenting of molecules that the company believes may stimulate the brain’s capacity to generate new neurons, potentially reversing pathophysiologies associated with certain central nervous system (CNS) conditions. The company has completed phase 1a and 1b trials evaluating NSI-189, a novel neurogenic small molecule product candidate, for the treatment of major depressive disorder or MDD, and is currently conducting a phase 2 efficacy study for MDD. Neuralstem’s stem cell therapy product candidate, NSI-566, is a spinal cord-derived neural stem cell line. Neuralstem is currently evaluating NSI-566 in three indications: stroke, chronic spinal cord injury (cSCI), and Amyotrophic Lateral Sclerosis (ALS). Neuralstem is conducting a phase 1 safety study for the treatment of paralysis from chronic motor stroke at the BaYi Brain Hospital in Beijing, China. In addition, NSI-566 was evaluated in a phase 1 safety study to treat paralysis due to chronic spinal cord injury as well as a phase 1 and phase 2a risk escalation, safety trials for ALS. Subjects from all three indications are currently in long-term observational follow-up periods to continue to monitor safety and possible therapeutic benefits. For more information, visit the company’s website at www.neuralstem.com.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
